High-risk papillomavirus (HR-HPV) testing combined with cytology improves the detection of cervical lesions and increases length of screening intervals. For a population-based HR-HPV survey, testing automation is in great need. The Cobas 4800 HPV Test System is a fully automated assay that can simultaneously detect HPV16, HPV18, and other 12 pooled HR-HPV genotypes. This system has been employed for HR-HPV screening in a number of countries; however, such application in a large population in China has not been documented. In this study, we employed the Cobas 4800 HPV Test System to detect HR-HPV in cervical cytology specimens collected from a total of 5650 asymptomatic women from a region of South China. We reported the following: (1) the p...
<div><p>Cervical cancer is caused by high-risk human papillomaviruses (HPV) and viral detection test...
Every year there are approximately 16,000 new cases of cervical cancer in Brazil. Novel screening te...
New, lower-cost tests that target high-risk human papillomavirus (HR-HPV) have been developed for ce...
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of ce...
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of ce...
Evaluation of the Cobas 4800 test demonstrated that Cobas had a low rate of cross-reactivity with lo...
AbstractBackgroundMolecular tests allow the detection of high-risk human papillomavirus in cervical ...
<div><p>Detecting high-risk (HR) HPV is important for clinical management of women with persistent H...
Objectives Determine the ability of the Cobas 4800 assay to detect high-risk human papillomavirus ...
This study evaluated the clinical performance of the cobas 4800 HPV Test (Roche Molecular Systems, P...
This study demonstrates that the clinical sensitivity, specificity, and reproducibility of the novel...
HPV testing in cervical cancer screening has been proposed as an alternative or complementary to cyt...
Human Papillomavirus (HPV) is the etiological agent for cervical cancer and genital warts. Worldwide...
This study proves that the novel Allplex II HPV28 assay has a good diagnostic performance in compari...
Cervical screening programmes are moving towards HPV testing as part of the screening process and as...
<div><p>Cervical cancer is caused by high-risk human papillomaviruses (HPV) and viral detection test...
Every year there are approximately 16,000 new cases of cervical cancer in Brazil. Novel screening te...
New, lower-cost tests that target high-risk human papillomavirus (HR-HPV) have been developed for ce...
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of ce...
New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of ce...
Evaluation of the Cobas 4800 test demonstrated that Cobas had a low rate of cross-reactivity with lo...
AbstractBackgroundMolecular tests allow the detection of high-risk human papillomavirus in cervical ...
<div><p>Detecting high-risk (HR) HPV is important for clinical management of women with persistent H...
Objectives Determine the ability of the Cobas 4800 assay to detect high-risk human papillomavirus ...
This study evaluated the clinical performance of the cobas 4800 HPV Test (Roche Molecular Systems, P...
This study demonstrates that the clinical sensitivity, specificity, and reproducibility of the novel...
HPV testing in cervical cancer screening has been proposed as an alternative or complementary to cyt...
Human Papillomavirus (HPV) is the etiological agent for cervical cancer and genital warts. Worldwide...
This study proves that the novel Allplex II HPV28 assay has a good diagnostic performance in compari...
Cervical screening programmes are moving towards HPV testing as part of the screening process and as...
<div><p>Cervical cancer is caused by high-risk human papillomaviruses (HPV) and viral detection test...
Every year there are approximately 16,000 new cases of cervical cancer in Brazil. Novel screening te...
New, lower-cost tests that target high-risk human papillomavirus (HR-HPV) have been developed for ce...